David Arthur, President and CEO Salarius Pharmaceuticals (NASDAQ:SLRX) is poised to ride the growing epigenetic wave with a differentiated lead drug candidate, seclidemstat, in early clinical development for the...
THIS WEEK'S FEATURE
MORE FEATURES
NEWS
SVB Leerink ups Aclaris Therapeutics to OP; PT to $3.50 from $1.50
SVB Leerink upgraded Aclaris Therapeutics (NASDAQ:ACRS) to “outperform” from “market perform” and raised its price target to $3.50 from $1.50, citing a new focus at the company. The stock closed at $1.41 on Oct. 21...
Titan Pharma to present two Probuphine posters at conference
Titan Pharmaceuticals (NASDAQ:TTNP) will present two posters on its buprenorphine implant, Probuphine, at the tenth American Conference of Pharmacometrics. Probuphine is a subdermal implant that provides six-month...
FDA accepts IntelGenx NDA resubmission for RIZAPORT
The FDA accepted IntelGenx’s (TSXV:IGX; OTCQX:IGXT) 505(b)(2) NDA resubmission for RIZAPORT VersaFilm for the treatment of acute migraines. The FDA also assigned a PDUFA goal date for completion of the NDA review of...
Zenabis cultivation output of dried cannabis up 21.8% in September
Zenabis Global’s (TSX:ZENA) cultivation output of dried cannabis reached 2,089 kg in September 2019, or 21.2% greater than its revised forecast output of 1,731 kg. Output at the company’s Zenabis Atholville plant...
HCW starts Dynavax Technologies at buy; PT $13
H.C. Wainwright initiated coverage of Dynavax Technologies (NASDAQ:DVAX) with a “buy” rating and $13 price target based on an outlook for the sales growth of the company’s marketed hepatitis B vaccine, Heplisav-B. The...
JPET publishes Hepion data highlighting CRV431’s potential to treat chronic liver diseases
Hepion Pharmaceuticals (NASDAQ:HEPA) CRV431 data from experimental models of fibrosis and non-alcoholic steatohepatitis (NASH) have been published in the peer-reviewed Journal of Pharmacology and Experimental...
Dawson James starts Dyadic at buy; PT $14
Dawson James Securities launched coverage of Dyadic International (NASDAQ:DYAI) with a “buy” rating and $14 price target. The stock closed at $6.66 on Oct. 15. Dyadic has been developing a gene expression platform over...
Kane Biotech, Dechra Veterinary expand license and distribution agreement to include South America
Kane Biotech (TSXV:KNE) and Dechra Veterinary Products, a unit of Dechra Pharmaceuticals (LSE:DPH), expanded their 10-year exclusive license and distribution agreement to include South America. The agreement was...
Stifel starts IGM Biosciences at buy; PT $32
Stifel launched coverage of IGM Biosciences (NASDAQ:IGMS) with a “buy” rating and $32 price target. The stock closed at $17.25 on Oct. 11. “We believe the company’s first/only-in-class, IgM-based antibody platform...
Just a few of the companies we’ve highlighted along the way
